Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan. [...] Valeant Chairman and CEO Michael Pearson said Thursday that his company is committed to health care innovation and funding important research. Valeant said the potential glaucoma drug, Vesneo, lowered eye pressure in late-stage research on patients with glaucoma or ocular hypertension.